Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-08-16
2011-08-16
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C435S069100, C435S069700, C514S012200, C530S350000, C536S023700
Reexamination Certificate
active
07998489
ABSTRACT:
The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
REFERENCES:
patent: 6168932 (2001-01-01), Uckun et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 7052702 (2006-05-01), Duggan et al.
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 7811584 (2010-10-01), Steward et al.
patent: 2002/0137886 (2002-09-01), Lin et al.
patent: 2003/0124147 (2003-07-01), Vallera et al.
patent: 2003/0180289 (2003-09-01), Foster et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2008/0032930 (2008-02-01), Steward et al.
patent: 2008/0032931 (2008-02-01), Steward et al.
patent: 2008/0081355 (2008-04-01), Dolly et al.
patent: 2008/0161226 (2008-07-01), Steward et al.
patent: 2008/0161543 (2008-07-01), Steward et al.
patent: 2008/0182294 (2008-07-01), Dolly et al.
patent: WO 94/21300 (1994-09-01), None
patent: WO 01/07072 (2001-02-01), None
patent: WO 01/94411 (2001-12-01), None
patent: WO 2004/024909 (2004-03-01), None
patent: WO 2005/023309 (2005-03-01), None
patent: WO 2006/027207 (2006-03-01), None
patent: WO 2006/059093 (2006-06-01), None
patent: WO 2006/059105 (2006-06-01), None
patent: WO2006/059113 (2006-06-01), None
Tsui, J.K.,Botulinum Toxin as a Therapeutic Agent,Pharmacol. Ther. 72(1):13-24 (1996).
Trejo, J.,Protease-Activated Receptors: New Concepts in Regulation of G Protein-Coupled Receptor Signaling and Trafficking,J. Pharmacol. Exp. Ther. 307(2): 437-442 (2003).
Scarborough, R.M.,Protease-Activated Receptor-2 Antagonists and Agonists,Curr. Med. Chem. Cardiovasc. Hematol. Agents 1(1): 73-82 (2003).
U.S. Appl. No. 11/572,512, filed Jan. 23, 2007, Steward et al.
U.S. Appl. No. 10/931,719, filed Sep. 1, 2004, Li et al.
Pastan, I., FitzGerald, D.,Pseudomonas Exotoxin: Chimeric Toxins,J. Biol. Chem. 264(26): 15157-15160 (1989).
Ossovskaya, V.S., Bennett, N. W.,Protease-Activated Receptors: Contribution to Physiology and Disease,Physiol. Rev. 84(2): 579-621 (2004).
MacFarlane, S.R. et al., Protease-Activated Receptors, Pharmacol. Rev. 53(2) 245-282 (2001).
O'Brien, P.J. et al., Protease Activated Receptors: Theme and Variations, Oncogene 20(13) 1570-1581 (2001).
Hollenberg, M.D., Compton, S.J.,International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors,Pharmacol. Rev. 54(2): 203-217 (2002).
Hirano, K., Kanaide, H.,Role of Protease Activated Receptors in The Vascular System,J. Atheroscler. Thromb. 10(4): 211-225 (2003).
Gaborik Z., Hunyady, L.,Intracellular Trafficking of Hormone Receptors,Trends Endocrinol. Metab. 15(6): 286-293 (2004).
Faruqi, T.R. et al.,Structure-Function Analysis of Protease-Activated Receptor 4 Tethered Ligand Peptides. Determinants of Specificity and Utility in Assays of Receptor Function,J. Biol. Chem. 275(26): 19728-19734 (2000).
Chackalamannil, S.,G-protein Coupled Receptor Antagonists-1: Protease Activated Receptor-1 (PAR-1) Antagonists as Novel Cardiovascular Therapeutic Agents,Curr. Top. Med. Chem. 3(10): 1115-1123 (2003).
Cottrell, G.S. et al.,Protease-Activated Receptor 2: Activation, Signalling and Function,Biochem. Soc. Trans. 31(6):1191-1197 (2003).
Cottrell, G.S. et al., Protease-Activated Receptors:The Role of Cell-Surface Proteolysis in Signalling,Essays Biochem. 38:169-183 (2002).
Coughlin, S.R.,Thrombin Signalling and Protease-Activated Receptors,Nature 407(6801): 258-264 (2000).
Derian, C.K. et al.,Therapeutic Potential of Protease-Activated Receptor-1 Antagonists,Expert Opin. Investig. Drugs 12(2): 209-221 (2003).
Coelho, A-M et al.,Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles,Curr. Med. Chem. Cardiovasc. Hematol. Agents 1(1): 61-72 (2003).
Herreros et al, “C-Terminal Half of Tetanus Toxin Fragment C is Sufficient for Neuronal Binding and Interaction with a Putative Protein Receptor”, Biochemical Journal, vol. 347, No. Part 1, pp. 199-204, Apr. 1, 2001.
Rummel et al, “The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interation”, Molecular Microbiology, pp. 631-643, Dec. 15, 2003.
Halpern et al, “Characterization of the receptor-binding domain of tetanus toxin”, Journal of Biological Chemistry, pp. 11188-11192, May 25, 1993.
Aoki Kei Roger
Fernandez-Salas Ester G.
Francis Joseph
Gilmore Marcella A.
Li Shengwen
Abel Kenton
Allergan Inc.
Condino Debra
Kam Chih-Min
LandOfFree
Degradable clostridial toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Degradable clostridial toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Degradable clostridial toxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711167